Quantinno Capital Management LP boosted its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 24.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 271,089 shares of the company's stock after acquiring an additional 53,849 shares during the quarter. Quantinno Capital Management LP's holdings in Sanofi were worth $13,061,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Advisory Services Network LLC boosted its position in Sanofi by 1.4% in the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company's stock valued at $743,000 after buying an additional 210 shares in the last quarter. Savant Capital LLC raised its stake in shares of Sanofi by 2.7% in the fourth quarter. Savant Capital LLC now owns 8,623 shares of the company's stock valued at $418,000 after acquiring an additional 225 shares during the last quarter. Wesbanco Bank Inc. boosted its holdings in shares of Sanofi by 4.9% in the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company's stock worth $239,000 after acquiring an additional 230 shares in the last quarter. IFG Advisory LLC grew its position in Sanofi by 2.7% during the 4th quarter. IFG Advisory LLC now owns 9,213 shares of the company's stock worth $446,000 after acquiring an additional 244 shares during the last quarter. Finally, Cohen Investment Advisors LLC grew its position in Sanofi by 2.9% during the 1st quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company's stock worth $457,000 after acquiring an additional 263 shares during the last quarter. 14.03% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the company. Citigroup reissued a "neutral" rating on shares of Sanofi in a research note on Monday, April 13th. Weiss Ratings raised Sanofi from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, May 13th. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a report on Saturday. Argus upgraded shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 27th. Finally, BNP Paribas Exane downgraded shares of Sanofi from an "outperform" rating to a "neutral" rating and set a $50.00 target price for the company. in a research note on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, Sanofi currently has a consensus rating of "Hold" and an average price target of $49.50.
Read Our Latest Research Report on Sanofi
Sanofi Price Performance
Shares of SNY stock opened at $42.95 on Tuesday. The firm has a market cap of $104.13 billion, a price-to-earnings ratio of 22.49, a PEG ratio of 1.15 and a beta of 0.35. Sanofi has a 12 month low of $40.89 and a 12 month high of $52.68. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. The stock has a 50-day moving average price of $43.41 and a 200 day moving average price of $45.16.
About Sanofi
(
Free Report)
Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.
Key commercial offerings include specialty biologics and established small-molecule medicines.
Featured Stories
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
